Sumitomo Pharma Co., Ltd.
4506
Rank in Stocks
#3254
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Share Price
$12.09
Market Cap
$5.42B
Change (1 day)
0.65%
Change (1 year)
5.10%
Country
JP
Trade Sumitomo Pharma Co., Ltd. (4506)
Category
Healthcare
Operating Margin for Sumitomo Pharma Co., Ltd. (4506)
Operating Margin as of October 2026 TTM: 10.05%
According to Sumitomo Pharma Co., Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 10.05%. At the end of 2024 the company had an Operating Margin of -112.60%.
Operating Margin history for Sumitomo Pharma Co., Ltd. from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 10.05% | 39.20% |
| 2025 | 7.22% | -106.41% |
| 2024 | -112.60% | 712.41% |
| 2023 | -13.86% | -228.81% |
| 2022 | 10.76% | -22.03% |
| 2021 | 13.80% | -19.95% |
| 2020 | 17.24% | 36.83% |
| 2019 | 12.60% | -33.30% |
| 2018 | 18.89% | 47.35% |
| 2017 | 12.82% | 39.96% |
| 2016 | 9.16% | 46.09% |
| 2015 | 6.27% | -42.32% |
| 2014 | 10.87% | 50.97% |
| 2013 | 7.20% | 23.71% |
| 2012 | 5.82% | -28.68% |
| 2011 | 8.16% | -32.11% |
| 2010 | 12.02% | 1.86% |
| 2009 | 11.80% | -21.75% |
| 2008 | 15.08% | -13.53% |
| 2007 | 17.44% | 48.43% |
| 2006 | 11.75% | 77.49% |
| 2005 | 6.62% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -97.72% |
IN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.